NCT05290610 Intracranial Stimulation Mapping In Epilepsy
| NCT ID | NCT05290610 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Minnesota |
| Condition | Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2022-06-01 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2022-06-01 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single group prospective study to determine the feasibility for generating brain maps that localize cerebral functions and inter-regional information flow in partial epilepsy in adult patients.
Eligibility Criteria
Inclusion Criteria: * Male or female 18 years and older at screening. * Written informed consent is obtained from the participant to comply with the requirements of the study. * Stated willingness to comply with all study procedures and availability for the duration of the study * Currently undergoing clinically indicated intracranial EEG monitoring for planning of epilepsy surgery in the University of Minnesota/MINCEP program. Exclusion Criteria: * Pregnancy ruled out prior to approval for intracranial EG monitoring. * Persons who are rendered temporarily or permanently invulnerable by inability to understand the research due to study complexity, cognitive impairment, or by inability to make independent decisions owing to University of Minnesota or to Fairview health services.
Contact & Investigator
Alexander Herman, MD
PRINCIPAL INVESTIGATOR
UMN
Frequently Asked Questions
Who can join the NCT05290610 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05290610 currently recruiting?
Yes, NCT05290610 is actively recruiting participants. Contact the research team at maple036@umn.edu for enrollment information.
Where is the NCT05290610 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT05290610 clinical trial?
NCT05290610 is sponsored by University of Minnesota. The principal investigator is Alexander Herman, MD at UMN. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.